We're transitioning — thanks for your patience!
As part of Repligen’s recent acquisition of the Process Analytics Technology (PAT) portfolio from 908 Devices, we are in the process of migrating all related resources to our website. This includes application notes, white papers, technical documents, and other educational materials that may have previously been available on the 908 Devices website.
We understand this transition may cause a temporary disruption if you were searching for specific documents or resources, and we sincerely apologize for the inconvenience.
In the meantime, we’re here to help—please choose the option that best fits your needs:
- Looking for a specific resource or document?
Email us directly at [email protected] and our team will do their best to assist you. - Interested in learning more about our newly acquired Upstream PAT solutions?
Connect with a PAT specialist to discuss your application and explore how Repligen’s expanded portfolio can support your bioprocessing goals.
We appreciate your patience during this transition and look forward to supporting your success.
Newly acquired Upstream PAT Solutions
For Cell Culture Media Analysis
REBEL XT
Analyze fresh or spent media and get quantitative reports for amino acids, dipeptides, water soluble vitamins and biogenic amines.
For Bioprocessing
Maverick
Raman-based, in-line monitoring and control of key bioprocessing parameters across up to six bioreactors simultaneously.
For Glucose & Lactate
Maven
Real-time glucose and lactate monitoring provides valuable insights and control without compromising bioreactor or fermenter volume.
For Biological Characterization
ZipChip
Rapid protein characterization for efficient, accurate, and comprehensive analysis of multiple CQAs.
A Note from Repligen
At Repligen, we’re committed to advancing bioprocessing through innovation, collaboration, and insight. With the integration of 908 Devices’ powerful PAT technologies—REBEL™, MAVERICK™, MAVEN™, and more—we’re expanding our PAT portfolio to deliver greater access to real-time insights and control for upstream and downstream applications.
This transition represents more than just a change in ownership, it reflects our shared vision to accelerate therapeutic development and empower scientists and manufacturers with deeper, faster insights into their processes.
We appreciate your understanding during this time and thank you for your continued trust as we bring together the best of both worlds.